Latest Earnings Results: Q3 '26
Estimated EPS
-$0.26
Reported EPS
-$0.14
Surprise
+46.15%
Estimated Rev
$0.5M
Reported Rev
$1.6M
Surprise
+220%
• Reported GAAP EPS of -$0.70 up 41.67% YoY • Reported revenue of $1.6M down -42.86% YoY • DBV Technologies estimates its existing cash and cash equivalents will fund operations into the third quarter of 2027; as of September 30, 2026, cash and equivalents totaled $165.7M.
Bullish Takeaway
DBV Technologies submitted its 4-through-7-year-old VIASKIN Peanut BLA supported by the 654-child VITESSE study, is advancing toddler development, and is preparing U.S. launch and dedicated manufacturing capacity.
Bearish Takeaway
DBV Technologies reported substantial doubt about its ability to continue as a going concern and requires additional capital; quarterly losses widened as operating expenses rose, while sole-source manufacturing faces FDA cGMP remediation risk.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.26 | -- | -- | N/A |
Q3 '26 | -$0.26 | -$0.14 | 46.15% | BEAT |
Q2 '26 | -$0.12 | -$0.12 | -3.45% | MISSED |
Q1 '26 | -$0.13 | -$0.11 | 17.91% | BEAT |
Q4 '25 | -$0.16 | -$0.24 | -50.00% | MISSED |